Revista Brasileira de Reumatologia
versão impressa ISSN 0482-5004
FRAGOSO, Thiago Sotero et al. Rituximab in the refractory Felty's syndrome. Rev. Bras. Reumatol. [online]. 2009, vol.49, n.2, pp. 188-190. ISSN 0482-5004. http://dx.doi.org/10.1590/S0482-50042009000200010.
The authors report a case of a 29 year old woman who has seropositive rheumatoid arthritis for six months, and developed severe granulocytopenia and important splenomegaly, however she didn´t show any joint inflammation. She did not respond either to pulse or oral steroids, or to oral methotrexate and leflunomide. She also developed an adverse reaction to the use of infliximab and did not respond well to adalimumab. Although she has had repeated infections, despite the various forms of antibiotics and long-term use of G-CSF, with high titers of rheumatoid factor, and high levels of ESR and CRP, the classic Rituximab method for treating rheumatoid arthritis was used. There was a good clinical response with an increase in the number of neutrophils following normalization of them, together with the reduction of rheumatoid factor titers, ESR and CRP. At the moment, the patient is in remission, according to both clinical and laboratory criteria and taking 5mg of prednisone per day and 10mg of methotrexate per week.
Palavras-chave : rheumatoid arthritis; Felty's syndrome; treatment; rituximab.